Effectiveness and safety of vedolizumab and infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis: A multicenter, retrospective cohort study.

Rui Ping MengBao Bao HuangYan Ling WeiLin LyuHuan YangCheng LiuHong Li ZhouXi Ping LiaoJian Yun ZhouXia Xie

Published in: Journal of digestive diseases (2024)

VDZ and IFX showed comparable clinical efficacy and safety profiles and can be used as viable first-line therapeutic options for biologic-naïve patients with moderate-to-severe UC.

Keyphrases

ulcerative colitis
rheumatoid arthritis
high intensity
early onset
drug induced